Teams at the University of Washington School of Pharmacy and Fred Hutch will model the clinical and economic burden of sickle cell disease and the potential benefits of emerging therapies
A new Science Translational Medicine paper is first to report how editing a portion of stem cells with CRISPR/Cas9 is sufficient for long-term reactivation of therapeutic hemoglobin
<p>Dr. Rainer Storb receives $12.9M to study blood stem-cell therapies for immune deficiencies; Dr. Julie Overbaugh studies HIV 'superinfection' to provide clues for better vaccine design</p>